Tirzepatide, a dual GLP-1R and glucose-dependent insulinotropic polypeptide (GIP) agonist, is also an emerging therapy that has demonstrated superior efficacy to injectable semaglutide in improving glycemic control in the SURPASS-2 (Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes) trial.59 GIP agonism is a promising target as it enhances the lipid-lowering and fat deposition effects of GLP-1 and may have a synergistic effect in attenuating CV risk. The gene discussed is GIP; the disease is type 2 diabetes mellitus.